Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
409
Frequently Asked Questions
What is market cap of Cytokinetics Inc?
The market cap of Cytokinetics Inc is $3.33B
What is the 52 week high for Cytokinetics Inc?
The 52 week high for Cytokinetics Inc is $55.80.
What is the 52 week low for Cytokinetics Inc?
The 52 week low for Cytokinetics Inc is $32.96.
What is Cytokinetics Inc stock price today?
Cytokinetics Inc' stock price today is $35.19.
What is the pe ratio of Cytokinetics Inc?
The PE ratio of Cytokinetics Inc is -8.23.
What is the price to book ratio of Cytokinetics Inc?
The price to book ratio of Cytokinetics Inc is -30.7441.
What is Cytokinetics Inc's EBITDA?
Cytokinetics Inc's EBITDA is -315.803.
What is the 50-day moving average of Cytokinetics Inc?
The 50-day moving average of Cytokinetics Inc is 40.7934.